|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Securities available-for-sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Commercial | ||||||||||||||||||||
| Residential | ||||||||||||||||||||
| Consumer | ||||||||||||||||||||
| Total loans | ||||||||||||||||||||
| (Less) plus: Net deferred loan (fees)/costs | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Restricted stock | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other real estate owned | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Non-interest-bearing | ||||||||||||||||||||
| Interest-bearing: | ||||||||||||||||||||
| Certificates of deposit exceeding the FDIC insurance limits | ||||||||||||||||||||
| Other interest-bearing deposits | ||||||||||||||||||||
| Total Deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Common stock, $0.125 stated value per share; Authorized shares - 40,000,000; Issued shares-16,206,804 in 2026 and 16,190,157 in 2025; Outstanding shares - 11,891,896 in 2026 and 11,880,759 in 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Less: Treasury shares at cost - 4,314,908 in 2026 and 4,309,398 in 2025 | ||||||||||||||||||||
| TOTAL SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, stated value per share | ||||||||||||||||||||
Loading...
